PL2994148T3 - Terapia nowotworowa - Google Patents

Terapia nowotworowa

Info

Publication number
PL2994148T3
PL2994148T3 PL14723864T PL14723864T PL2994148T3 PL 2994148 T3 PL2994148 T3 PL 2994148T3 PL 14723864 T PL14723864 T PL 14723864T PL 14723864 T PL14723864 T PL 14723864T PL 2994148 T3 PL2994148 T3 PL 2994148T3
Authority
PL
Poland
Prior art keywords
cancer therapy
cancer
therapy
Prior art date
Application number
PL14723864T
Other languages
English (en)
Polish (pl)
Inventor
Thorsten Hagemann
Original Assignee
Immodulon Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immodulon Therapeutics filed Critical Immodulon Therapeutics
Publication of PL2994148T3 publication Critical patent/PL2994148T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
PL14723864T 2013-05-09 2014-05-09 Terapia nowotworowa PL2994148T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1308325.8A GB201308325D0 (en) 2013-05-09 2013-05-09 Cancer Therapy
EP14723864.6A EP2994148B8 (en) 2013-05-09 2014-05-09 Cancer therapy

Publications (1)

Publication Number Publication Date
PL2994148T3 true PL2994148T3 (pl) 2017-07-31

Family

ID=48672024

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14723864T PL2994148T3 (pl) 2013-05-09 2014-05-09 Terapia nowotworowa

Country Status (18)

Country Link
US (1) US20160074494A1 (cg-RX-API-DMAC7.html)
EP (1) EP2994148B8 (cg-RX-API-DMAC7.html)
JP (1) JP2016520057A (cg-RX-API-DMAC7.html)
KR (1) KR20160022803A (cg-RX-API-DMAC7.html)
CN (1) CN105407901A (cg-RX-API-DMAC7.html)
AU (1) AU2014264434A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015025719A2 (cg-RX-API-DMAC7.html)
CA (1) CA2907841A1 (cg-RX-API-DMAC7.html)
DK (1) DK2994148T3 (cg-RX-API-DMAC7.html)
ES (1) ES2618050T3 (cg-RX-API-DMAC7.html)
GB (1) GB201308325D0 (cg-RX-API-DMAC7.html)
HU (1) HUE031783T2 (cg-RX-API-DMAC7.html)
MX (1) MX2015014344A (cg-RX-API-DMAC7.html)
PL (1) PL2994148T3 (cg-RX-API-DMAC7.html)
RU (1) RU2015143106A (cg-RX-API-DMAC7.html)
SG (1) SG11201507847UA (cg-RX-API-DMAC7.html)
SI (1) SI2994148T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014181121A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
WO2016207646A1 (en) * 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
KR101832892B1 (ko) * 2015-08-24 2018-02-27 가톨릭대학교 산학협력단 면역억제제로 유발되는 미토콘드리아 질환 및 면역 질환의 예방 또는 치료를 위한 메트포민을 포함하는 조성물
GB201601248D0 (en) * 2016-01-22 2016-03-09 Immodulon Therapeutics Ltd Cancer therapy
GB201608806D0 (en) * 2016-05-19 2016-07-06 Immodulon Therapeutics Ltd Method
WO2018112364A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018112360A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
WO2019075452A1 (en) * 2017-10-13 2019-04-18 Evelo Biosciences, Inc. IDENTIFICATION OF BACTERIA FOR CANCER THERAPY
CN109329204B (zh) * 2018-10-12 2021-02-12 中国医学科学院北京协和医院 胰腺癌动物模型的构建方法
CN117286186A (zh) * 2022-06-16 2023-12-26 中国医学科学院北京协和医院 胰腺癌动物模型的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
CA2369542C (en) 1999-04-23 2009-10-27 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
WO2006109300A1 (en) 2005-04-14 2006-10-19 Hadasit Medical Research Services & Development Ltd. Pre-transplantation treatment of donor cells to control graft versus host disease (gvhd) in transplant recipients
WO2008110491A2 (en) * 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
EP2085466A1 (en) * 2008-01-29 2009-08-05 AEterna Zentaris GmbH Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
AU2010270030B2 (en) * 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
US8617520B2 (en) * 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy

Also Published As

Publication number Publication date
BR112015025719A2 (pt) 2017-07-18
CA2907841A1 (en) 2014-11-13
EP2994148B1 (en) 2017-02-01
ES2618050T3 (es) 2017-06-20
JP2016520057A (ja) 2016-07-11
EP2994148B8 (en) 2017-08-30
MX2015014344A (es) 2016-06-21
CN105407901A (zh) 2016-03-16
SI2994148T1 (sl) 2017-07-31
WO2014181121A1 (en) 2014-11-13
DK2994148T3 (en) 2017-03-13
KR20160022803A (ko) 2016-03-02
US20160074494A1 (en) 2016-03-17
GB201308325D0 (en) 2013-06-19
HUE031783T2 (en) 2017-07-28
EP2994148A1 (en) 2016-03-16
RU2015143106A (ru) 2017-06-15
SG11201507847UA (en) 2015-11-27
AU2014264434A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
GB201322725D0 (en) Cancer therapy
IL245731A0 (en) Combined treatment for cancer
HUE057061T2 (hu) Kombinációs terápia rák kezelésére
SG11201509707QA (en) Cancer therapy
SG11201507847UA (en) Cancer therapy
SG11201508223YA (en) Treatment of cancer with dihydropyrazino-pyrazines
ZA201507733B (en) Treatment of cancer with dihydropyrazino-pyrazines
EP3007756A4 (en) Catheter-assisted tumor treatment
ZA201507755B (en) Tumor-selective combination therapy
GB201308440D0 (en) Therapeutic
ZA201505937B (en) Caix stratification based cancer treatment
EP2961412A4 (en) CANCER THERAPY
EP3044593A4 (en) Cancer therapy
GB201310755D0 (en) Therapy
GB201403083D0 (en) Treatment of cancer
GB201318668D0 (en) Sonosensitive therapeutic
EP3007704A4 (en) Combination therapy
GB201307269D0 (en) Combination Therapy
GB201308039D0 (en) Photodynamic therapy
GB201518731D0 (en) Tumour Therapy
EP3013332A4 (en) Cancer treatment
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
GB201309967D0 (en) Therapeutic combinations
GB201317213D0 (en) Cancer Therapy
GB201308365D0 (en) Tumour therapy